Diabetic kidney disease is the leading cause of end-stage renal disease globally, affecting approximately 40% of people with diabetes. SGLT2 inhibitors and finerenone have demonstrated significant renoprotective effects beyond renin-angiotensin system blockade. Early intervention, tight metabolic control, and integrated nephrology-endocrinology care pathways are essential to slowing disease progression.
Loading articles...
